Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
506 articles
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.
A prospective cohort study shows combining ctDNA with PSA levels dramatically improves survival prediction in high-volume metastatic prostate cancer patients.
A Swiss feasibility trial tests digital mindfulness-based cancer recovery, tracking psychosocial outcomes, medication use, and biological markers.
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.
A Swiss study of 100,000 cases over 40 years reveals colorectal cancer rising steadily in younger adults, with late diagnoses alarmingly common.
Stanford scientists used RFdiffusion and ProteinMPNN to build a compact α-helical TCR mimic with 9.5 nM affinity for a tumor antigen — and near-perfect peptide specificity.
A new machine learning tool called MaNeo scans tumor peptides to identify neoantigens that activate T cells against cancer while sparing healthy cells.
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
